. Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe. Am J Physiol Endocrinol Metab 286: E252-E260, 2004. First published October 21, 2003 10.1152/ajpendo.00424.2003.-Thiazolidinediones address underlying causes of type 2 diabetes, although their mechanism of action is not clearly understood. The compounds are thought to function as direct activators of the nuclear receptor PPAR␥ (peroxisome proliferator-activated receptor-␥), although pioglitazone, the weaker agonist of the two thiazolidinediones now in clinical use, seems to have more useful effects on circulating lipids. We have used tritiated pioglitazone and a photoaffinity crosslinker to identify a novel binding site in mitochondria. A saturable binding site for [
insulin sensitizers; thiazolidinediones; photoaffinity probes; novel site of action; mitoNEET THIAZOLIDINEDIONES WERE FIRST DESCRIBED by the Takeda Company as lipid-lowering, antidiabetic agents in the early 1980s (6, 14, 22) . Treatment of animals resulted in improvement of insulin action in all of the target tissues, and various lines of evidence suggested that the pharmacology of these compounds was secondary to improved insulin sensitivity (8, 21) . The work of Kletzien and colleagues (18, 26, 27) provided the biochemical basis for the hypothesis that these agents produce their effect in vitro by direct interaction with the nuclear receptor peroxisome proliferator-activated receptor-␥ (PPAR␥) (31, 43) . The correlation of these studies in vitro on the differentiation of adipocytes and antidiabetic action extended the hypothesis to suggest that the lipid-lowering and antidiabetic actions of these molecules were secondary to direct activation of PPAR␥ (40, 43, 48) .
Although there have been considerable attempts to exploit this hypothesis (36) , and structural information regarding the putative target is available (46) , there are no superior drugs on the horizon. Furthermore, there are some inconsistencies in the hypothesis that direct activation of PPAR␥ might explain all of the pharmacology. Thus not all PPAR␥ activators have antidiabetic actions (30) , and some potent antidiabetic analogs are not good PPAR␥ activators (5, 37, 42) . Partial reduction in PPAR␥ expression results in increased insulin sensitivity (33) , and naturally occurring mutations also do not offer a clear picture (e.g., 17, 19, 44) . Finally, in humans, pioglitazone (Actos), a weaker activator of PPAR␥ (31) , generally produces a greater reduction in circulating lipids (reduction in triglycerides and total cholesterol/HDL cholesterol) than does the more potent activator rosiglitazone (Avandia) (2, 15, 24, 29) .
Given the lack of certainty about the mechanism of action of this important class of drugs (28, 35) , we have explored the possibility of an alternate site of binding of the thiazolidinediones. We have approached this problem by using high specific activity tritiated pioglitazone and a structurally related iodinated photoaffinity probe.
MATERIALS AND METHODS

Probes. [
3 H]pioglitazone was generated by tritium exchange from the dibromo derivative at 31.7 Ci/mmol and was stored in methanol. PNU-101074 was synthesized by coupling a carboxylic acid analog of pioglitazone (PNU-91323) to a p-azido-benzyl group containing ethylamine (Fig. 1) . The purified compound was iodinated, carrier-free, with Iodogen (Pierce), and 125 I-PNU-101074 was purified on a C18 column and stored in the dark. These radioactive probes and competitor compounds are shown in Fig. 1 . Competitor compounds, to show the selectivity of binding/cross-linking, were made as previously described (45) .
Membrane isolation. Crude rat liver, skeletal muscle, and brain mitochondrial-enriched fractions were prepared as follows. Briefly, Sprague-Dawley rats were anesthetized, and hindleg muscle, liver, and whole brain were removed to a cold buffer, MLB (in mM: 225 sucrose, 6 K 2HPO4, 5 MgCl2, 20 KCl, and 2 EGTA, pH 7.4). Tissues were chopped, rinsed, and homogenized with a polytron (setting 7; 3ϫ, 15 s) in 5 volumes of MLB. After removal of the unbroken cells and nuclei (750 g), the mitochondrial-enriched fraction was collected at 15,800 g for 5 min. The loose pellet was discarded, and the dense central pellet was resuspended in MLB and recollected at 11,800 g for 10 min. The final pellets were resuspended in 50 mM Tris (pH 8) at 5-8 mg/ml total protein and frozen at Ϫ80°C. Bovine brain mitochondria were harvested from steer brains. The rinsed brains were homogenized in fractionation buffer (250 mM sucrose, 50 mM Tris, pH 8.0, containing 1 mg/ml pepstatin A, 5 mg/ml leupeptin, 10 mg/ml bacitracin, and 0.1 mM PMSF). After removal of nuclei at 2,250 rpm in a Sorval SS-34 rotor, the mitochondrial pellet was harvested at 20,000 g (13,000 rpm in a Sorval SS-34 rotor) and further enriched by sucrose density centrifugation. Membrane fractions were collected from the top of the 1.18 and 1.20 density bands, resuspended in 50 mM Tris, and collected by centrifugation. The fractions ("B3/B4") were stored at Ϫ80°C until use. Lower-density bands were collected as controls. Succinate cytochrome c reductase was used as the mitochondrial marker (12) , and protein was measured by the bicinchoninic acid method (Pierce).
3T3-L1 preadipocytes were grown and differentiated as previously described (41) . Preadipocytes or fully differentiated adipocytes (11 days) were lifted off the plate with trypsin, and the cells were washed with Dulbecco's PBS and homogenized with 15 strokes with a motor-driven Teflon homogenizer. For the differentiated adipocytes, both floating and pelleted cells were included. After removal of the low-speed (750 g) pellet, the second pellet was collected at 18,000 g for 10 min. The pellets were resuspended in 50 mM Tris (pH 8), equalized for protein content, and used for cross-linking and Western blots as we will describe.
Binding and cross-linking assays. [ 3 H]pioglitazone binding was conducted using intact mitochondrial fractions and also fractions solubilized in 20 mM 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS). Intact membrane solutions were thawed and diluted to a concentration of 1 mg/ml in 50 mM Tris, pH 8.0. The reactions were conducted in 1.5-ml polypropylene microfuge tubes. The assay volume was 400 l, containing 100 l of membranes, 100 l of 0.4% gamma globulin, 100 l of 4% DMSO with or without the indicated concentration of competitor, and 100 l of [ 3 H]pioglitazone (0.2 Ci). The tubes were mixed and incubated at ambient temperature on a rocker for 60 min. Bound counts were detected after sedimentation of membranes (18,000 g, 5 min). For study of the solubilized binding, membrane stocks were solubilized in 20 mM CHAPS, and bound counts were separated from free ones with dextran-coated charcoal (5% charcoal/0.5% dextran in 50 mM Tris, pH 8.0). All binding assays were conducted in triplicate.
Cross-linking reactions were carried out in a final volume of 200 l, containing 100 l of membranes (adjusted for total protein), 50 ml of 4% DMSO with or without competing thiazolidinedione (TZD; e.g., 100 M PNU-91325, 25 M final concentration), and 50 l of carrier-free 125 I-PNU-101074 (0.1-0.2 Ci/tube). Specific cross-linking was defined as labeling that was prevented in the presence of competing active TZD (29) . An appropriate amount of 125 I-PNU-101074 in acetonitrile was dried under vacuum in the dark immediately before use. The reactions were incubated for 15 min at room temperature and stopped by exposure to UV light in open tubes (180,000 J in a Stratalinker). The cross-linked samples were then rinsed with 50 mM Tris (pH 8.0) after centrifugation at 18,000 g for 5 min. The rinsed pellets were resuspended in 100 l of 50 mM Tris.
Purification and identification of cross-linked protein. Optimal selective solubilization of the specifically cross-linked protein (m17) was obtained by bringing the resuspended pellet to 1% Triton X-114. After rocking at room temperature for 5 min, the bulk of the crosslinked m17 was recovered in the supernatant after centrifugation at 18,000 g for 15 min. The cross-linked m17 also remained in the supernatant after centrifugation at 450,000 g in a Beckman TLA 100 ultracentrifuge for 30 min. This removed many of the contaminating proteins.
Triton X-114 was removed from the sample by precipitation and flotation of the detergent with ammonium sulfate. The addition of equal volumes of 1.5 M ammonium sulfate to the Triton X-114 solution precipitated the proteins, leaving the detergent in solution. The precipitation procedure was repeated 3 times to maximize the yield of precipitated protein. Special care was taken to ensure that the protein precipitate did not float on the Triton-containing supernatant. The precipitated protein was concentrated for direct separation on SDS-PAGE gels (10-20% or 18% Tris-glycine) or for HPLC.
HPLC was conducted by using both UV scanning diode array detector and an in-line gamma-C flow cell (Packard). Purification of the m17 protein was achieved with a Phenomenex Synergi MAX-RP C12 column (4.6 ϫ 250 mm, 4 m). The guard column was a 4 ϫ 2.0-mm RP-1 SecurityGuard Cartridge (Phenomenex). The selections of the column and guard columns were made after considerable examination of standard protein columns, which gave no appreciable yield of the target protein. Samples were eluted with a programmed gradient elution starting with 70% solution A [water-0.05% trifluoracetic acid (TFA), vol/vol] and 30% solution B (Can-0.05% TFA, vol/vol). The gradient was held at 30% B for the first 15 min; B was then increased from 30 to 55% over 30 min and then increased to 80% over 15 min. Flow rates were fixed at 1 ml/min.
The specifically cross-linked proteins were excised from electrophoretic gels and were reduced, alkylated, and digested in situ with modified porcine trypsin (Promega) by use of a DigestPro robot (ABIMED). Briefly, protein gel spots were placed in reaction vials and secured in a Peltier heating/reaction block. Digested peptides were extracted with 60% acetonitrile-5% formic acid. Peptide extracts were placed in a Speed-Vac centrifuge until dry and were reconstituted in 10 l of 5% formic acid in water.
NanoLC tandem mass spectrometry analysis (nanoLC-MS/MS) was performed on a Micromass Qtof ultima instrument coupled to a Micromass CapLC. Typically, 5 l from a total sample amount of 5.5 l were injected and preconcentrated using column switching. An auxiliary pump was used to preconcentrate and desalt samples on a C18 Pepmap precolumn (0.3 ϫ 5 mm) by delivering 0.1% formic acid at 20 l/min. After desalting, the precolumn was switched in-line with the analytical column (75-mm-ID C 18 Pepmap, LC Packings) and eluted at 300 nl/min with a gradient of 0.1% formic acid in water and 0.1% formic acid containing 90% acetonitrile directly into the Qtof. Tandem MS data were acquired and processed by Micromass MassLyxn software. Nanospray MS/MS data were used to identify proteins by comparing the experimental data with predicted data derived from protein and DNA databases. Tandem MS data were searched against A procedure was developed to elute the m17 after SDS-PAGE with a series of rehydration and drying steps. The individual lane bands were cut out, and groups of 10 gel slices were placed in microfuge tubes, rehydrated in 0.5 ml of water, and nutated for 1 h at room temperature. The eluted material was retained, and the gel slices were then dried in a Speed-Vac centrifuge; this procedure was repeated two additional times. The pooled, eluted m17 was concentrated and resolved on SDS-PAGE before MS/MS identification or used for generation of CNBr fragments in 70% formic acid (overnight at room temperature). CNBr fragments were released by water elution. No further recovery occurred by electroelution of these gels. The samples were finally concentrated, run on 18% Tris-glycine gels (Invitrogen), and blotted to Immobilon-Psq (Millipore). The blots were stained with 0.1% Coomassie R-250, destained, air dried, and exposed to Biomax MS film at Ϫ80°C. Amino-terminal sequencing was performed by automated Edman degradation on an Applied Biosystems model 492 Procise cLC protein sequencer.
Generation of antibodies and Western blotting. The protein identified from cross-linking with PNU-101074 was evaluated for potential antigenic peptides with a set of computer programs developed in-house by F. J. Kezdy and R. A. Poorman. Three peptides were chosen and synthesized on an Applied Biosystems 433A peptide synthesizer by use of a HBTU/NMP protocol with the Fmoc (9-fluorenylmethoxycarbonyl) group as the NH 2-or amino-protecting group. The crude peptides were precipitated, purified by reverse-phase HPLC (Vydac C 18, 22 ϫ 250 mm, 10 m), and characterized by open access electrospray mass spectrometry.
Peptides A (CGGKAMVNLQIQKDDPKVV-OH), B (KV-VHAFDMGDLGDKAVWC-OH), and C (CGGNEETGDNVGPLI-IKKKET) (compare with sequence in Fig. 5 ) were sent to Covance Research Products (Denver, PA) for conjugation to keyhole limpet hemocyanin and immunization of rabbits. Serum was tested against a spotted concentration-dose curve (0.01-10 mg) against all peptides. Positive reactions were obtained from the first bleed onward for peptides A and B. Peptide C did not elicit an immune response. Antisera to A or B did not cross-react to any of the other peptides. Western analysis was conducted by running protein samples on reducing 18% Tris-glycine gels and blotting to polyvinyldifluoride membranes. The blotted membranes were incubated with a 1:30,000 dilution of anti-mitoNEET peptide B. Detection of the immunoreactive bands was determined by incubating with a 1:50,000 dilution of alkaline phosphatase-conjugated monoclonal anti-rabbit IgG (Sigma no. A-2556) followed by development with BCIP/NBT Blue Liquid Substrate (Sigma no. B-3804). Anti-prohibitin (1:400 dilution; Research Diagnostics) was used as a mitochondrial protein marker (23) . The developed blots were dried and exposed to Biomax MS film.
Association of mitochondrial proteins with the synthetic target. The 108-amino acid protein identified as the putative target of TZD cross-linking was synthesized by solid phase to contain an NH 2- terminal biotin for attachment of streptavidin agarose (4%) beads (Sigma, S-1638). Peptide with or without an NH 2-terminal biotin extension (25 g/50 l bead suspension) was incubated in a total volume of 250 l for 1 h at 4°C, followed by addition of 50 l of 1 mM biotin and 200 l of the solubilized mitochondrial preparation and incubation for an additional 2 h. The beads were then washed 6 times with 1 ml of 10 mM Tris, 150 mM NaCl, and 0.4 mM CHAPS. Proteins were eluted with a minimal volume (60 l) of 0.1 M glycine and 150 mM NaCl, pH 2.3. There was no binding of solubilized mitochondrial proteins to beads alone or beads plus the peptide not containing the NH 2-terminal biotin.
RESULTS
A saturable binding site for [ 3 H]pioglitazone was found in crude mitochondrial membranes from bovine brain ( Fig. 2A) . Similar results were obtained with crude mitochondrial membranes from rat liver, skeletal muscle, and differentiated 3T3-L1 adipocytes. In these studies, half-maximal binding occurred between 0.1-and 1-m pioglitazone. No specific binding was measured in any other cellular fractions (see below). The binding activity was solubilized by CHAPS. The soluble binding had similar characteristics to the binding in the intact membranes and showed the same specificity with competition by unlabeled pioglitazone, but less competition by ciglitazone (Fig. 2B) , which itself is considered to have little activity (20) .
Attempts to isolate the soluble [ 3 H]pioglitazone-binding fraction met with little success. The activity migrated as a large complex in the void volume of size-exclusion columns and as a single peak on ion exchange, but the activity was rapidly lost, especially when the samples were not kept at a pH close to 8 (not shown). A photoaffinity probe was made to mark the site of attachment of the TZD for further characterization. As shown in Fig. 3A , a single specifically cross-linked band (competed by the active TZD, PNU-91325) marked by the arrow (m17), was found in the crude mitochondrial fraction obtained from a variety of tissue sources. Competition for cross-linking of this band by both pioglitazone and ciglitazone was similar to the competition for [ 3 H]pioglitazone binding (Fig. 3B) . Furthermore, both [ 3 H]pioglitazone binding (Fig.  3C ) and cross-linking of the m17 protein (Fig. 3D) 
The cross-linked band could not be resolved by two-dimensional gel electrophoresis (not shown), a technique that has proven successful for other proteins identified by this technique (9). The specifically cross-linked band was purified from bovine brain and rat liver mitochondria by two approaches. Cross-linked mitochondria were solubilized with 1% Triton X-114, also resulting in a partial enrichment with respect to total protein. Further enrichment and concentration of m17 were accomplished by precipitating the solubilized crosslinked protein with 0.75 M ammonium sulfate (AS). This was the optimal concentration of AS that allowed precipitation of the protein while keeping the Triton in solution. Concentration and removal of the Triton X-114 were essential for optimal separation by HPLC (see below).
The concentrated m17 was separated by HPLC, as described in MATERIALS AND METHODS. Identical results were obtained from either fresh rat liver mitochondrial samples or bovine brain mitochondrial fractions, suggesting that a similar target protein was involved. A representative pattern of the separation by HPLC is shown in Fig. 4A . Identification of the radioactive peak was simplified by the in-line radiometric detector (Fig.  4A, bottom right) . The m17 peak eluted at ϳ30 min under these conditions at ϳ55% acetonitrile. Parallel runs with samples from cross-linking incubations that contained the competitor PNU-91325 lacked this peak (not shown). SDS-PAGE together with autoradiography demonstrated that this method provides a successful purification of the specifically PNU-101074-crosslinked protein (Fig. 4) .
The m17 cross-linked protein was also concentrated in high yield by a water elution procedure from unfixed, unstained gels (Fig. 4B) . For this approach, 80 individual tubes were crosslinked with or without PNU-91325, solubilized with Triton X-114, concentrated by AS precipitation, and then subjected to SDS-PAGE on 18% Tris-glycine gels that were not fixed or stained. The bands of interest were marked and cut out as described in MATERIALS AND METHODS. Figure 4B shows an autoradiogram of a representative gel before and after the band of interest was cut out for water elution of the cross-linked m17 band. Reexposure of these gels confirmed that the center of the Values are means Ϯ SE for triplicate measurements. These data are from an intact bovine brain mitochondrial preparation and are representative. Similar data were generated using crude rat skeletal muscle mitochondria (not shown). C: correlation of specific binding of [ 3 H]pioglitazone binding (fmol/mg, ordinate) vs. specific activity of mitochondrial marker succinate cytochrome c reductase (cyt c red'ase, abscissa). These data are from sucrose density gradient bands derived from a 20,000-g pellet of bovine brain, as described in text. D: the same subcellular fractions described in C were used for cross-linking with 125 I-PNU-101074. Counts/mg protein (ordinate) were correlated with the mitochondrial marker succinate cytochrome c reductase (abscissa). Correlations shown were repeated in independent experiments. specific band had been excised. This procedure produced the highest yield of m17 cross-linked protein.
Purified m17 bands from unfixed, unstained 18% Trisglycine gels were rinsed and processed for proteomic identification, as described in MATERIALS AND METHODS. Preparations from both rat liver mitochondria and bovine mitochondrial fractions identified the same tryptic peptides shown in bold in Fig. 5A . These sequences are annotated "similar to hematopoietic stem/progenitor cells protein MDS029" ID gi 15488774: (BC013522). The mouse protein sequence is shown. The predicted human and mouse proteins are virtually identical.
We attempted to confirm the identification by NH 2 -terminal sequencing. Sequencing of the intact protein was unsuccessful, suggesting that the NH 2 terminus might be blocked. Gel digestion with CNBr generated a Ͻ6-kDa cross-linked fragment. The blot showing the intact and CNBr-digested fragment is shown in Fig. 5B . Partial sequence data were obtained from this fragment supporting the MS/MS identification of the labeled protein (Fig. 5B) .
We next sought to generate antibodies against this protein.
Three peptides from the predicted non-membrane-spanning region were selected and synthesized. Antisera generated against both peptide A and peptide B recognized the m17 on Western blots; however, the greatest reactivity was with the serum generated from rabbits immunized with peptide B. Figure 6 demonstrates a representative Western blot of crosslinking reactions with sucrose density fractions obtained from bovine brain. As predicted from previous results, the crosslinked band was enriched in the higher-density protein bands that are enriched in mitochondrial marker (in agreement with results shown in Fig. 3, C and D) . After SDS-PAGE, representative gels for these samples were transferred to membranes for Western blots using preimmune (Fig. 6, top  left) , anti-peptide B (Fig. 6, top center) , or anti-prohibitin, a known mitochondrial protein (23) (Fig. 6, top right) . Prohibitin and m17 immunoreactivity were in the same fractions, and the m17 staining was overlaid by the TZDspecific cross-linking (Fig. 6, bottom) representative panels. The antibody also recognized a protein band of the same size as the specifically cross-linked band in rat liver and skeletal muscle mitochondrial fractions; other cell fractions were negative (not shown).
A further correlation of the m17 protein by Western blot analysis and cross-linking by the TZD probe is shown in Fig.  7 . As can be seen in the autoradiograms depicting the TZDspecific cross-linking, there is little cross-linking (Fig. 7, B and  D, lanes 1-4) and no measurable immunostaining in the Western blots (Fig. 7C) in the crude membranes from preadipocytes (lanes 1-4) , whereas both end points are found in membranes from the differentiated cells (lanes 5-8) . Overexposure of the autoradiograms did demonstrate very low levels of cross-linking in the preadipocytes (not shown).
Although antibodies against the m17 peptides recognized the intact protein, they were not useful for immunoprecipitation purposes (not shown). Because the tritiated pioglitazone-binding activity in solubilized membranes migrated as a large complex (see RESULTS), we assumed that the m17 might associate with other mitochondrial proteins and that this might provide some hint as to its function. The 108-amino acid protein was synthesized by a solid-phase approach with an NH 2 -terminal biotin and fastened to Streptavidin beads, as described in MATERIALS AND METHODS. Solubilized mitochondrial preparations were then incubated with the beads with or without the attached synthetic protein. Figure 8 shows an example of a silver-stained gel containing the contents released from these beads. In the absence of peptide (Ϫ, beads only), no bound proteins were eluted when the pH of the washing solution was reduced. In the presence of the peptide (ϩ), a Gels contained the intact protein (m17) and the Ͻ6-kDa CNBr-digested fragment that still contained the cross-linked probe (m6). NH2-terminal sequence data are shown (X ϭ cycle residue not identified) and compared with sequence predicted by data described in A. Matching amino acids are in bold, and arrow in A shows point of CNBr cleavage. Fig. 6 . Western blot for putative target of 125 I-PNU-101074 cross-linking. Cross-linking reactions were conducted on sucrose density gradient bands from subcellular fractions of bovine brain mitochondria, as described in text and in Fig. 3 , C and D. Samples were subjected to electrophoresis on 3 polyacrylamide gels, blotted, and then incubated with preimmune serum (left), antibodies to m17 peptide B (center), or antibodies to mitochondrial protein prohibitin (right). Western blots (top) were conducted and developed as described in text. Blots were then exposed to film, and respective autoradiogram images are shown at left. The same results were obtained from a 2nd experiment.
subset of proteins was eluted from beads incubated with solubilized mitochondria from brain, skeletal muscle, or liver. The protein bands were cut from the gel and identified by nanoLC-MS/MS, as described in MATERIALS AND METHODS. A representative data set obtained from a solubilized rat liver mitochondria preparation is shown in Table 1 . The subset of proteins collected by m17 from mitochondria from various sources included complex 3, ATP synthase, and enzymes involved in ␤-oxidation of fatty acids.
DISCUSSION
Although thiazolidinediones are useful in treating type 2 diabetes and have been increasingly used in the treatment of the disease (1, 47) , the exact mechanism of action of these compounds remains to be defined (28) . As outlined in the introduction, it is generally assumed that the overall pharmacology is secondary to direct activation of the nuclear receptor PPAR␥ (31, 34, 40, 43, 48) . It has been hypothesized that some effects may be secondary to direct activation of PPAR␥ in adipose tissue; however, the pharmacology is not necessarily dependent on adipose tissue (4). As we discussed, there are some additional complexities unexplained by the hypothesis that these compounds are simple activators of PPAR␥. Fur- Fig. 7 . Western blot for putative target in 3T3-L1 fibroblasts and adipocytes. Pellets (18,000 g) were made from 3T3-L1 preadipocytes (fibroblasts) and fully differentiated adipoctyes, as described in text, and equalized for total protein. Cross-linking reactions were run without (Ϫ) or with (ϩ) excess unlabeled TZD. Samples without (odd numbers) and with (even numbers) competitors were conducted in duplicate for preadipoctye (fibroblast) (lanes 1-4) and adipocyte (lane 5-8) pellets. Samples were then subjected to electrophoresis and stained for protein with Coomassie blue (A) or used for Western blots with antisera to peptide B (C). Respective autoradiograms are shown beneath stained gel (B) and blot (D). Fig. 8 . Binding of solubilized mitochondrial proteins to synthetic m17 kDa target protein. Synthetic m17 kDa target was synthesized with an NH2-terminal biotin. The protein was made both with and without the sequence in bold that contains the putative transmembrane sequence. Synthetic proteins were bound to streptavidin-agarose, and "catch experiments" were conducted, as described in text, using mitochondrial fractions from rat brain, skeletal muscle, or liver. Proteins eluted by reduced pH were subjected to electrophoresis on a 10% polyacrylamide gel under reducing conditions and silver stained. Lanes (Ϫ) were from beads incubated without the biotinylated protein. Lanes (ϩ) were from beads preincubated with synthetic peptide shown. Similar results were obtained when biotinylated protein without the transmembrane sequence was used. Protein bands were cut from the gel and identified as described in text. Fig. 8 were analyzed text. A representative analysis from a rat liver mitochondrial sample is shown. thermore, other direct actions of the compounds have been reported, such as inhibition of an acyl-CoA synthase (25) and direct effects on skeletal muscle (3) . Several groups have suggested that thiazolidinediones may have different effects in different tissues (13, 51) . Resolution of the key site of thiazolidinedione interaction that leads to useful pharmacology would undoubtedly help in the production of improved therapeutic agents.
We found that high specific activity (Fig. 3) .
Two approaches were taken to purify the protein from two tissue sources, bovine brain and rat liver. One involved selective solubilization with Triton X-114, followed by reversephase HPLC and SDS-PAGE electrophoresis. The second approach involved preparative scale electrophoresis followed by elution of the cross-linked protein from the unfixed gels, CNBr cleavage, and then electrophoresis and sequencing of the labeled fragment. The partially purified fractions submitted to trypsin digestion and MS/MS analysis, as described in MATE-RIALS AND METHODS, identified two common tryptic peptides from both tissue sources on three different occasions (Fig. 5) . The identification was confirmed by NH 2 -terminal sequencing of the 6-kDa CNBr fragment produced after preparative scale electrophoresis (Fig. 5B) .
To provide more evidence for support of the identification, antibodies were generated to allow measurement of the protein by Western blot. In support of the findings, the antibodies recognized a protein of the same size in the same tissue fractions. Importantly, both the protein and cross-linking were undetectable under standard conditions in cultured preadipoctyes, and both were measurable upon differentiation of the cells into adipocytes. The common detection under these conditions supports the conclusion that we have identified the mitochondrial protein that is cross-linked by the thiazolidinedione probe. The increased expression upon differentiation of adipocytes suggests that the protein may be involved in lipid metabolism.
Because we were unable to immunoprecipitate the crosslinked protein with the anti-peptide antibodies, we asked whether the synthetic protein would bind to solubilized mitochondrial proteins. Chromatography of soluble binding studies with tritiated pioglitazone had indicated that the mitochondrial target was associated with a large number of proteins. The identification of these proteins might provide insight as to function. The synthetic target protein bound a set of mitochondrial proteins, including components of complex 3, ATP synthase, and pyruvate dehydrogenase. Of particular interest was the association of key enzymes involved in fatty acid oxidation, especially the trifunctional enzyme complex (11) . On the basis of its unique sequence and mitochondrial location, we suggest the name mitoNEET for this previously unidentified target for the thiazolidinediones. MitoNEET may serve as a supporting framework upon which mitochondrial metabolism can be channeled and controlled.
It is well known that insulin resistance is associated with elevated tissue levels of long-chain acyl-CoA esters (10) . Furthermore, treatment of animals with pioglitazone can lower the tissue levels of long-chain acyl-CoA esters and even protect against their buildup during lipid infusions (49) . The buildup of long-chain acyl-CoA esters could result in insulin resistance by a number of mechanisms, including activation of specific protein kinase C isoforms (50) or generation of ceramide (7) . Thiazolidinediones could improve insulin sensitivity secondary to lowering the long-chain CoAs after a direct interaction with this novel mitochondrial target. Such an effect could include more efficient oxidation (11) , perhaps even including a feedforward effect by keeping malonyl-CoA levels in check (38, 39) .
In conclusion, a novel mitochondrial target protein has been identified for the insulin-sensitizing thiazolidinediones. This protein may play a role in regulating mitochondrial oxidation of fatty acids, and modulation of this target may be involved in the mechanism of action of these drugs. The groundwork is now laid to test this hypothesis. Because PPAR␥ is known to be centrally involved in the production of new fat stores (32) and induction of glycerol kinase (16) , promoting the storage of fat, it is possible that elimination of direct modulation of PPAR␥ while maintaining the mitochondrial interaction may produce an improved therapeutic profile.
